Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23
Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. The availability of a range of novel, targeted therapies for their treatment, most notably the availability o...
Main Authors: | K. M. Darch, T. L. Holland, L. J. Spelman |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Case Reports in Medicine |
Online Access: | http://dx.doi.org/10.1155/2020/9404505 |
Similar Items
-
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021-01-01) -
Secukinumab for plaque psoriasis
by: Gonzalo Ordenes-Cavieres, et al.
Published: (2018-11-01) -
Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
by: Raja Natarajan
Published: (2019-01-01) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01) -
Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
by: Alessio Gambardella
Published: (2019-09-01)